Morgan Stanley lowered the firm’s price target on Accelerant (ARX) to $17 from $18 and keeps an Equal Weight rating on the shares. The firm updated models in the insurance space post the Q3 reports. For property and casualty, Morgan Stanley sees a softening cycle heading into 2026, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARX:
- Tiger Global buys Netflix, exits Eli Lilly in Q3
- Accelerant price target lowered to $15 from $18 at Piper Sandler
- Accelerant Holdings Reports Significant Loss Amid Revenue Growth
- Accelerant Holdings Class A: Strong Performance and Promising Growth Prospects Drive Buy Rating
- Accelerant reports Q3 adjusted EPS 38c, consensus 21c